Skip to main content
PMC home page
British Journal of Sports Medicine logoLink to British Journal of Sports Medicine
. 2004 Jun;38(3):253–259. doi: 10.1136/bjsm.2003.000199

Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a)

F Hartgens 1, G Rietjens 1, H Keizer 1, H Kuipers 1, B Wolffenbuttel 1
PMCID: PMC1724824  PMID: 15155420

Abstract

Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes.

Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2-C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined.

Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l. Serum Lp(a) declined from 189 (315) to 32 (63) U/l. Total cholesterol and triglycerides did not change significantly. Alterations after eight and 14 weeks of AAS administration were comparable. No changes occurred in the controls. Six weeks after AAS cessation, serum HDL-C, HDL2-C, Apo-A1, Apo-B, and Lp(a) had still not returned to baseline concentrations. Administration of AAS for 14 weeks was associated with slower recovery to pretreatment concentrations than administration for eight weeks. In study 2, nandrolone decanoate did not influence serum triglycerides, total cholesterol, HDL-C, HDL2-C, HDL3-C, Apo-A1, and Apo-B concentrations after four and eight weeks of intervention, nor six weeks after withdrawal. However, Lp(a) concentrations decreased significantly from 103 (68) to 65 (44) U/l in the nandrolone decanoate group, and in the placebo group a smaller reduction from 245 (245) to 201 (194) U/l was observed. Six weeks after the intervention period, Lp(a) concentrations had returned to baseline values in both groups.

Conclusions: Self administration of several AASs simultaneously for eight or 14 weeks produces comparable profound unfavourable effects on lipids and lipoproteins, leading to an increased atherogenic lipid profile, despite a beneficial effect on Lp(a) concentration. The changes persist after AAS withdrawal, and normalisation depends on the duration of the drug abuse. Eight weeks of administration of nandrolone decanoate does not affect lipid and lipoprotein concentrations, although it may selectively reduce Lp(a) concentrations. The effect of this on atherogenesis remains to be established.

Full Text

The Full Text of this article is available as a PDF (74.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Applebaum-Bowden D., Haffner S. M., Hazzard W. R. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism. 1987 Oct;36(10):949–952. doi: 10.1016/0026-0495(87)90130-2. [DOI] [PubMed] [Google Scholar]
  2. Bhasin S., Woodhouse L., Casaburi R., Singh A. B., Bhasin D., Berman N., Chen X., Yarasheski K. E., Magliano L., Dzekov C. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172–E1181. doi: 10.1152/ajpendo.2001.281.6.E1172. [DOI] [PubMed] [Google Scholar]
  3. Cohen L. I., Hartford C. G., Rogers G. G. Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc. 1996 Feb;28(2):176–179. doi: 10.1097/00005768-199602000-00004. [DOI] [PubMed] [Google Scholar]
  4. Crook D., Sidhu M., Seed M., O'Donnell M., Stevenson J. C. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 1992 Jan;92(1):41–47. doi: 10.1016/0021-9150(92)90008-5. [DOI] [PubMed] [Google Scholar]
  5. Cushing G. L., Gaubatz J. W., Nava M. L., Burdick B. J., Bocan T. M., Guyton J. R., Weilbaecher D., DeBakey M. E., Lawrie G. M., Morrisett J. D. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989 Sep-Oct;9(5):593–603. doi: 10.1161/01.atv.9.5.593. [DOI] [PubMed] [Google Scholar]
  6. Friedl K. E., Dettori J. R., Hannan C. J., Jr, Patience T. H., Plymate S. R. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J Steroid Biochem Mol Biol. 1991;40(4-6):607–612. doi: 10.1016/0960-0760(91)90283-b. [DOI] [PubMed] [Google Scholar]
  7. Friedl K. E., Hannan C. J., Jr, Jones R. E., Plymate S. R. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990 Jan;39(1):69–74. doi: 10.1016/0026-0495(90)90150-b. [DOI] [PubMed] [Google Scholar]
  8. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med. 1991 Oct;151(10):1925–1933. [PubMed] [Google Scholar]
  9. Haffner S. M., Kushwaha R. S., Foster D. M., Applebaum-Bowden D., Hazzard W. R. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983 Apr;32(4):413–420. doi: 10.1016/0026-0495(83)90052-5. [DOI] [PubMed] [Google Scholar]
  10. Kostner G. M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G. B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981 Jan-Feb;38(1-2):51–61. doi: 10.1016/0021-9150(81)90103-9. [DOI] [PubMed] [Google Scholar]
  11. Kostner G. M. Lipoprotein Lp(a): impact on atherosclerosis and immunochemical quantification. Przegl Lek. 1989;46(7):560–562. [PubMed] [Google Scholar]
  12. Kreisberg Robert A., Oberman Albert. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab. 2002 Feb;87(2):423–437. doi: 10.1210/jcem.87.2.8057. [DOI] [PubMed] [Google Scholar]
  13. Kronenberg F., Kronenberg M. F., Kiechl S., Trenkwalder E., Santer P., Oberhollenzer F., Egger G., Utermann G., Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation. 1999 Sep 14;100(11):1154–1160. doi: 10.1161/01.cir.100.11.1154. [DOI] [PubMed] [Google Scholar]
  14. Lippi G., Guidi G., Ruzzenente O., Braga V., Adami S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest. 1997 Oct;57(6):507–511. doi: 10.3109/00365519709084601. [DOI] [PubMed] [Google Scholar]
  15. Luke J. L., Farb A., Virmani R., Sample R. H. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci. 1990 Nov;35(6):1441–1447. [PubMed] [Google Scholar]
  16. MBewu A. D., Durrington P. N. Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis. 1990 Nov;85(1):1–14. doi: 10.1016/0021-9150(90)90177-k. [DOI] [PubMed] [Google Scholar]
  17. Nieminen M. S., Rämö M. P., Viitasalo M., Heikkilä P., Karjalainen J., Mäntysaari M., Heikkilä J. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996 Oct;17(10):1576–1583. doi: 10.1093/oxfordjournals.eurheartj.a014724. [DOI] [PubMed] [Google Scholar]
  18. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H. J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 Sep-Oct;9(5):579–592. doi: 10.1161/01.atv.9.5.579. [DOI] [PubMed] [Google Scholar]
  19. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990 Dec 1;301(6763):1248–1251. doi: 10.1136/bmj.301.6763.1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Scanu A. M. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988 Oct;112(10):1045–1047. [PubMed] [Google Scholar]
  21. Scanu A. M. Lipoprotein(a): a genetically determined lipoprotein containing a glycoprotein of the plasminogen family. Semin Thromb Hemost. 1988 Jul;14(3):266–270. doi: 10.1055/s-2007-1002788. [DOI] [PubMed] [Google Scholar]
  22. Sharrett A. R., Ballantyne C. M., Coady S. A., Heiss G., Sorlie P. D., Catellier D., Patsch W., Atherosclerosis Risk in Communities Study Group Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001 Sep 4;104(10):1108–1113. doi: 10.1161/hc3501.095214. [DOI] [PubMed] [Google Scholar]
  23. Singh Atam B., Hsia Stanley, Alaupovic Petar, Sinha-Hikim Indrani, Woodhouse Linda, Buchanan Thomas A., Shen Ruoquing, Bross Rachelle, Berman Nancy, Bhasin Shalender. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002 Jan;87(1):136–143. doi: 10.1210/jcem.87.1.8172. [DOI] [PubMed] [Google Scholar]
  24. Taggart H. M., Applebaum-Bowden D., Haffner S., Warnick G. R., Cheung M. C., Albers J. J., Chestnut C. H., 3rd, Hazzard W. R. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism. 1982 Nov;31(11):1147–1152. doi: 10.1016/0026-0495(82)90166-4. [DOI] [PubMed] [Google Scholar]
  25. Teruel J. L., Lasuncion M. A., Rivera M., Aguilera A., Ortega H., Tato A., Marcen R., Ortuño J. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis. 1997 Apr;29(4):569–575. doi: 10.1016/s0272-6386(97)90340-1. [DOI] [PubMed] [Google Scholar]
  26. Teruel J. L., Lasuncion M. A., Rivera M., Aguilera A., Ortega H., Tato A., Marcen R., Ortuño J. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis. 1997 Apr;29(4):569–575. doi: 10.1016/s0272-6386(97)90340-1. [DOI] [PubMed] [Google Scholar]
  27. Thiery J., Armstrong V. W., Schleef J., Creutzfeldt C., Creutzfeldt W., Seidel D. Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr. 1988 May 16;66(10):462–463. doi: 10.1007/BF01745519. [DOI] [PubMed] [Google Scholar]
  28. Thompson P. D., Cullinane E. M., Sady S. P., Chenevert C., Saritelli A. L., Sady M. A., Herbert P. N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989 Feb 24;261(8):1165–1168. [PubMed] [Google Scholar]
  29. Utermann G. The mysteries of lipoprotein(a). Science. 1989 Nov 17;246(4932):904–910. doi: 10.1126/science.2530631. [DOI] [PubMed] [Google Scholar]
  30. Yesalis C. E., Barsukiewicz C. K., Kopstein A. N., Bahrke M. S. Trends in anabolic-androgenic steroid use among adolescents. Arch Pediatr Adolesc Med. 1997 Dec;151(12):1197–1206. doi: 10.1001/archpedi.1997.02170490023005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Sports Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES